Paradigm Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Paradigm Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-15,500	Closed	-$668K	–	505
2017 Q2	$668K	Sell	15,500 -16,000	-51%	-$569K	0.13%	163
2017 Q1	$986K	Sell	31,500 -3,000	-9%	-$80.4K	0.19%	121
2016 Q4	$871K	Sell	34,500 -1,000	-3%	-$22.3K	0.17%	110
2016 Q3	$878K	Buy	35,500 +30,750	+647%	+$696K	0.15%	107
2016 Q2	$96.8K	Hold	4,750	–	–	0.02%	460
2016 Q1	$72.4K	Sell	4,750 -9,300	-66%	-$121K	0.01%	517
2015 Q4	$189K	Sell	14,050 -2,800	-17%	-$43.3K	0.03%	366
2015 Q3	$236K	Buy	+16,850	New	+$313K	0.03%	443

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Paradigm Asset Management's SUPN Position: Q3 2017 in Review

Paradigm Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 15,500 shares — an estimated $668K sold.

Paradigm Asset Management first reported a position in SUPN in Q3 2015 and held it in 8 quarters. The position peaked at $986K in Q1 2017. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

Paradigm Asset Management reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Paradigm Asset Management sold 15,500 Supernus Pharmaceuticals shares in Q3 2017, an estimated $668K.
Paradigm Asset Management first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 8 quarters.
Paradigm Asset Management's Supernus Pharmaceuticals position peaked at $986K in Q1 2017.
275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.